Table 2.
Studies of intrathecal rituximab in progressive MS.
| Ref. | (n) ratioa |
EDSS baseline | Clinical/MRI activity (≤1year) | Rituximab protocol | Biomarkers |
|---|---|---|---|---|---|
| [8] | 23 1.5 : 1 |
6.5 2.5-7.0 |
Yes | IT LP 25 mg ×2 IV 200 mg ×2 |
IgG index, NFL, CXCL13, CCL19, sCD14: unchanged; IL12p40 -42%, BAFF +8%, sCD21, sCD27: minimal changes. |
| [9] | 23 1 : 0 |
6.5 4.0-7.5 |
No | IT Om. 25 mg ×3 | NFL, GFAP, MBP, Gal-9, sCD27, CXCL14: unchanged; CXCL13: minimal decrease. |
| [10] | 9 1 : 0 |
5.5 4.0-8.0 |
Yes | IT LP 5-10-15 mg |
λ FLC, CXCL13: unchanged; κFLC: minimal increase; BAFF: decreased |
| [11] | 8 1 : 0 |
6.0 | No | IT LP 25 mg ×2 | NFL, sCD21, sCD27, sCD14, CCL19, CCL21: unchanged; BAFF increased; CXCL13: decreased. |
| Our | 10 4 : 1 |
6.5 6.0-8.0 |
No | IT LP 20 mg ±IV 375 mg/m2 (1 : 1) |
IgG index, OCB, NFL, OPN: unchanged. |
IT: intrathecal; LP: lumbar puncture; Om.: Ommaya reservoir. aratio active : control.